Bladder Cancer

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma September 18, 2020

Enfortumab Vedotin-Ejfv Significantly Improved Overall Survival in Phase 3 EV-301 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer September 18, 2020

Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. September 18, 2020

Sequencing of PD-1/L1 Inhibitors and Carboplatin-Based Chemotherapy for Cisplatin-Ineligible Metastatic Urothelial Carcinoma. September 18, 2020

Urinary glycoproteomic profiling of non-muscle invasive and muscle invasive bladder carcinoma patients reveals distinct N-glycosylation pattern of CD44, MGAM, and GINM1. September 18, 2020

Current status and future perspectives of immunotherapy in bladder cancer treatment. September 18, 2020

Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer. September 17, 2020

Intratumoral CCR5+ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses. September 17, 2020

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment. September 17, 2020

5α-reductase inhibitors impact prognosis of urothelial carcinoma. September 17, 2020

1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression. September 17, 2020

Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center. September 17, 2020

Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. September 16, 2020

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions. September 16, 2020

Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. September 16, 2020

MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study. September 16, 2020

Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. September 16, 2020

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma - Expert Commentary September 15, 2020

The long non-coding RNA SNHG1 promotes bladder cancer progression by interacting with miR-143-3p and EZH2. September 15, 2020

Expression profile of microRNAs in bladder cancer and their application as biomarkers. September 15, 2020

Page 1 of 363